Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Roivant Sciences Ltd. (ROIV)

6.92   -0.07 (-1%) 03-24 16:00
Open: 6.99 Pre. Close: 6.99
High: 7.05 Low: 6.65
Volume: 5,320,409 Market Cap: 5,248(M)

Technical analysis

as of: 2023-03-24 4:29:25 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 9.38     One year: 10.43
Support: Support1: 6.58    Support2: 5.47
Resistance: Resistance1: 8.03    Resistance2: 8.93
Pivot: 7.91
Moving Average: MA(5): 7.5     MA(20): 7.94
MA(100): 7.35     MA(250): 5.34
MACD: MACD(12,26): -0.3     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.6     %D(3): 17.4
RSI: RSI(14): 35
52-week: High: 10  Low: 2.51
Average Vol(K): 3-Month: 2,845 (K)  10-Days: 5,060 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ROIV ] has closed above bottom band by 5.5%. Bollinger Bands are 20% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.06 - 7.11 7.11 - 7.15
Low: 6.53 - 6.59 6.59 - 6.64
Close: 6.83 - 6.92 6.92 - 6.99

Company Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Headline News

Mon, 27 Mar 2023
What Recent Market Trends Mean for Roivant Sciences Ltd.'s (ROIV ... - The News Heater

Fri, 24 Mar 2023
Svf Investments (Uk) Ltd Sells 12000000 Shares of Roivant ... - Defense World

Thu, 23 Mar 2023
Is Roivant Sciences Ltd (ROIV) Stock a Smart Investment Thursday? - InvestorsObserver

Tue, 21 Mar 2023
12 Best Biotech Stocks To Buy Under $20 - Yahoo Finance

Fri, 17 Mar 2023
Can Roivant Sciences Ltd (ROIV) Stock Rise to the Top of Healthcare Sector Friday? - InvestorsObserver

Thu, 16 Mar 2023
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 725 (M)
% Held by Insiders 1.6214e+008 (%)
% Held by Institutions 50.4 (%)
Shares Short 16,400 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 99
Return on Equity (ttm) -24.9
Qtrly Rev. Growth 5.042e+007
Gross Profit (p.s.) -8.26
Sales Per Share -50.73
EBITDA (p.s.) -3.28421e+008
Qtrly Earnings Growth -4.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -858 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales -0.14
Price to Cash Flow 2.92

Stock Dividends

Dividend 0
Forward Dividend 1.283e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.